Bristol Myers’ Abecma continues to face pressure ahead of FDA adcomm

Fourth-quarter US sales of Bristol Myers Squibb’s BCMA-targeting CAR-T therapy Abecma last year declined by 40% compared to the same period in 2022, primarily due to competitive pressure.

Abecma pulled in $56 million in US revenue and $100 million total worldwide, BMS reported in its earnings update Friday, figures that…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks